FI891463A0 - Foerfarande foer att oeka extracellulaer adenosin och att stabilisera mastceller. - Google Patents

Foerfarande foer att oeka extracellulaer adenosin och att stabilisera mastceller.

Info

Publication number
FI891463A0
FI891463A0 FI891463A FI891463A FI891463A0 FI 891463 A0 FI891463 A0 FI 891463A0 FI 891463 A FI891463 A FI 891463A FI 891463 A FI891463 A FI 891463A FI 891463 A0 FI891463 A0 FI 891463A0
Authority
FI
Finland
Prior art keywords
att
stabilisera
oeka
mastceller
extracellulaer
Prior art date
Application number
FI891463A
Other languages
English (en)
Other versions
FI891463A (fi
Inventor
Harry Edward Gruber
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of FI891463A0 publication Critical patent/FI891463A0/fi
Publication of FI891463A publication Critical patent/FI891463A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Discharge Heating (AREA)
  • Re-Forming, After-Treatment, Cutting And Transporting Of Glass Products (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Examining Or Testing Airtightness (AREA)
FI891463A 1987-07-29 1989-03-28 Foerfarande foer att oeka extracellulaer adenosin och att stabilisera mastceller. FI891463A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/079,657 US4912092A (en) 1986-03-27 1987-07-29 Methods for increasing extracellular adenosine and for stabilizing mast cells
PCT/US1988/002527 WO1989000854A1 (en) 1987-07-29 1988-07-29 Methods for increasing extracellular adenosine and for stabilizing mast cells

Publications (2)

Publication Number Publication Date
FI891463A0 true FI891463A0 (fi) 1989-03-28
FI891463A FI891463A (fi) 1989-03-28

Family

ID=22151963

Family Applications (1)

Application Number Title Priority Date Filing Date
FI891463A FI891463A (fi) 1987-07-29 1989-03-28 Foerfarande foer att oeka extracellulaer adenosin och att stabilisera mastceller.

Country Status (13)

Country Link
US (1) US4912092A (fi)
EP (2) EP0672418A3 (fi)
JP (1) JPH02500916A (fi)
AT (1) ATE135580T1 (fi)
AU (3) AU2315088A (fi)
BR (1) BR8807151A (fi)
CA (1) CA1335716C (fi)
DE (1) DE3855120T2 (fi)
DK (1) DK175978B1 (fi)
ES (1) ES2087061T3 (fi)
FI (1) FI891463A (fi)
GR (1) GR3019389T3 (fi)
WO (1) WO1989000854A1 (fi)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2597683B1 (fr) * 1986-04-22 1992-07-31 Battarel Claude Clavier a interrruption de rayonnement.
JPH03504728A (ja) * 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ，インコーポレイテッド Ａｉｃａリボシドの放出および血液グルコースの低減のための化合物および方法
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
KR920703068A (ko) * 1989-09-15 1992-12-17 폴 레이킨드 신경변성 질환의 치료방법
US5366440A (en) * 1989-10-06 1994-11-22 The Beth Israel Hospital Association Methods for treating disease states using oxidized lipoproteins in conjunction with chemotherapeutic effector agents
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
US6180616B1 (en) 1990-05-10 2001-01-30 Atsuo F. Fukunaga Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
IL99124A (en) * 1990-08-10 1998-02-22 Gensia Pharma Substituted imidazole analogs of aica riboside
US5777100A (en) * 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
IL99125A0 (en) * 1990-08-10 1992-07-15 Gensia Pharma Derivatives of imidazole analog of aica riboside and their use
US5308837A (en) * 1990-08-22 1994-05-03 Merrell Dow Pharmaceuticals Inc. 5'-amine substituted adenosine analogs as immunosuppressants
AU665184B2 (en) * 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
US5236908A (en) * 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
EP0599987A4 (en) * 1991-08-23 1995-02-01 Gensia Inc METHOD FOR LOWERING BLOOD LIPID LEVELS.
IL103294A0 (en) * 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
AU6297294A (en) * 1993-02-03 1994-08-29 Gensia, Inc. Adenosine deaminase inhibitor therapies
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
AU7319994A (en) * 1993-06-30 1995-01-24 Board Of Regents, The University Of Texas System Nucleotide preparation and uses thereof in wound healing
US6342484B1 (en) 1993-06-30 2002-01-29 Board Of Regents, The University Of Texas Systems Method and compositions for promotion of wound treatment
US5366960A (en) * 1993-08-26 1994-11-22 Warner-Lambert Company Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US5859017A (en) * 1994-04-01 1999-01-12 Cell Therapeutics, Inc. Method for inhibiting mast cell and basophil activation
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
EP1174141A3 (en) * 1996-01-23 2003-04-23 ICN Pharmaceuticals, Inc. Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes
AU720437B2 (en) * 1996-10-03 2000-06-01 Trustees Of The University Of Pennsylvania, The Compositions and methods for the identification and treatment of patients at risk for heart failure
WO1999024038A1 (en) 1997-11-07 1999-05-20 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
US6800616B2 (en) 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
US6680292B1 (en) 1998-11-20 2004-01-20 The Salk Institute For Biological Studies Pharmaceutical composition comprising ribavirin and growth factors and methods of use
AU2026900A (en) * 1998-11-20 2000-06-13 Salk Institute For Biological Studies, The Neuron stimulation by ribavirin, and analogs thereof
US6579857B1 (en) * 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
WO2001010449A1 (en) * 1999-08-09 2001-02-15 Trustees Of Boston University Method of maintaining vascular integrity using aicar (5-amino-4-imidazole riboside) and related compounds
BR0016415A (pt) * 1999-12-16 2002-12-24 Alcon Inc Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico
EP1269198A2 (en) * 2000-03-23 2003-01-02 Novartis AG Identification of mast/basophil activation inhibitors
US20020086835A1 (en) * 2000-05-22 2002-07-04 Law William R. Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
WO2001093873A1 (en) * 2000-06-06 2001-12-13 Trustees Of Boston University Use of aicar and related compounds
WO2001097816A1 (en) * 2000-06-16 2001-12-27 Brigham Young University Use of amp kinase activators for treatment of type 2 diabetes and insulin resistance
US20030212034A1 (en) * 2001-06-11 2003-11-13 Winder William W Method of treatment of obesity and paralyzed muscle and ergogenic aids
US20030212013A1 (en) * 2001-06-14 2003-11-13 Winder William W Use of amp kinase activators for treatment type 2 diabetes and insulin resistance
ES2192495B1 (es) * 2002-03-21 2005-02-16 Universidad De Barcelona Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
WO2004060146A2 (en) * 2002-12-30 2004-07-22 Purdue Research Foundation Method of treatment for central nervous system injury
US20060079479A1 (en) * 2004-10-13 2006-04-13 Italo Biaggioni Methods of inducing vasodilation
US7687473B2 (en) * 2005-01-07 2010-03-30 Health Research, Inc. 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism
MX2007012045A (es) * 2005-03-28 2008-01-16 Pericor Therapeutics Inc Composiciones y formulaciones para evitar o reducir efectos adversos a un paciente.
WO2007017512A1 (en) * 2005-08-09 2007-02-15 Cellzome Ag Treatment of inflammatory diseases
WO2007017505A2 (en) * 2005-08-09 2007-02-15 Cellzome Ag Treatment of metabolic diseases
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
US7811549B2 (en) * 2006-07-05 2010-10-12 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
WO2009092516A2 (en) * 2008-01-22 2009-07-30 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
EP3753565A1 (en) * 2008-10-03 2020-12-23 ViCardia Therapeutics, Inc. Aica riboside analogs for treatment of cardiac and other conditions
US20100261666A1 (en) * 2009-04-14 2010-10-14 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of myocardial dysfunction associated with sirs or sepsis
ES2569922T3 (es) * 2009-11-25 2016-05-13 Nestec S.A. Composiciones nutritivas, que incluyen un componente de alto contenido en proteínas y nucleótidos exógenos
US8895520B2 (en) 2011-10-26 2014-11-25 Universite Nice Sophia Antipolis Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
US20150031712A1 (en) 2013-03-12 2015-01-29 Moshe Rogosnitzky Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same
EA201890014A1 (ru) 2015-06-08 2018-07-31 О.Д. Окьюлар Дискавери Лтд. Терапевтические композиции, содержащие дипиридамол, наборы для лечения, содержащие эти композиции, и способы их производства
CN112739352B (zh) * 2018-08-06 2024-01-23 斯凯拉克生物科技有限责任公司 活化amp-活化的蛋白激酶的化合物及其用途
US11779590B2 (en) 2020-10-30 2023-10-10 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
AU529532B2 (en) * 1978-09-18 1983-06-09 Commonwealth Scientific And Industrial Research Organisation Frequency response analyser
EP0066909A3 (en) * 1981-05-15 1984-03-07 FISONS plc Imidazole derivatives, pharmaceutical compositions containing them and processes for their production
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
EP0623348A1 (en) * 1986-03-27 1994-11-09 GRUBER, Harry, Edward The use of AICA riboside and ribavirin for the preparation of a medicament for the treatment of allergies

Also Published As

Publication number Publication date
JPH02500916A (ja) 1990-03-29
AU2315088A (en) 1989-03-01
CA1335716C (en) 1995-05-30
AU8039394A (en) 1995-03-09
DK148889A (da) 1989-05-29
EP0301900A2 (en) 1989-02-01
AU1285592A (en) 1992-06-04
AU687112B2 (en) 1998-02-19
EP0672418A2 (en) 1995-09-20
EP0672418A3 (en) 1996-05-29
FI891463A (fi) 1989-03-28
EP0301900B1 (en) 1996-03-20
ATE135580T1 (de) 1996-04-15
GR3019389T3 (en) 1996-06-30
ES2087061T3 (es) 1996-07-16
BR8807151A (pt) 1989-10-17
DE3855120T2 (de) 1996-09-19
EP0301900A3 (en) 1989-09-20
DE3855120D1 (de) 1996-04-25
DK175978B1 (da) 2005-10-17
WO1989000854A1 (en) 1989-02-09
US4912092A (en) 1990-03-27
DK148889D0 (da) 1989-03-28

Similar Documents

Publication Publication Date Title
FI891463A (fi) Foerfarande foer att oeka extracellulaer adenosin och att stabilisera mastceller.
FI873492A (fi) Dipyridamol eller mopidamol och o-acetylsalicylsyra eller deras fysiologiskt uthaerdbara salter innehaollande laekemedelspreparats framstaellningsfoerfarande och deras anvaendning foer att foerhindra trombosbildning.
ATE63694T1 (de) Beleuchtungsanordnung fuer ein system zur behandlung eines patienten durch photoaktivierung.
SE438912B (sv) Polarografisk elektrodanordning for transkutan metning av syrepartialtryck i arteriellt blod
DE3587941T2 (de) Gerät zur vorläufigen reperfusionsbehandlung von herzanfallsymptomen.
SE7601540L (sv) Medel for faststellande av blod och hemoglobin i biologiska emnen
EP0151989A3 (en) Means for the treatment of cardiac diseases
ATE75141T1 (de) Waesserige abfuehrende loesung.
IT8267970A0 (it) Dispositivo per la somministrazione per via parenterale di agenti benefici particolarmente sangue e suoi sostituti
FI891283A (fi) Ifosfamid-mesna-lyofilisat och foerfarande foer dess framstaellning.
DE3173954D1 (en) Use of adenosin derivatives for the manufacture of psychopharmacons
IT1116032B (it) Composizione e procedimento per la determinazione della concentrazione del glucosio in fluidi corporei
SE8404283L (sv) Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar
SE8102456L (sv) Farmaceutisk komposition for oral administering och innehallande cytidindifosfokolin
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ES2052614T3 (es) Uso de factor xiii de coagulacion de la sangre humana para el tratamiento de la colitis ulcerosa.
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
DE3876425D1 (de) Gesteuerte verabreichung eines heilmittels an blut.
SE7903631L (sv) Forfarande for bestemning av kalciumnivan i blod
ATE105479T1 (de) Verfahren zur steigerung des phosphatidylcholins in vivo.
IT7828103A0 (it) Diagnostico rapido per la determinazione dell'acido urico in liquidi corporei.
IT1075255B (it) Procedimetno per estrarre l'eme-gruppo prostetico ferroso dell'emoglobina dagli scarti risultanti dalla purificazione delle proteine contenute nel sangue
ES2018082B3 (es) Fluoro-1 halogeno-1 dioxa-3,6 biciclo [4.1.0] heptano, procedimiento de preparacion y utilizacion.
IT213853Z2 (it) Sonda monouso per la determinazione del ph vaginale.

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: THE REGENTS OF THE UNIVERSITY OF